Parmjot Bains
MD, CEO & Director
[Audio Gap]
Grant, our CFO. We’ll be referring to the 4C quarterly activity report and presentation we lodged this morning with the ASX. The presentation is a summary of the more detailed 4C quarterly activity report. After our remarks, we’ll be answering questions. You can lodge questions throughout the presentation using the Investor Hub QA function.
So let’s begin with Slide 3 with a quick overview of the agenda for today’s call. We’ll start with a business overview, including key highlights and take you through the updates for the 3 business segments. I’ll then hand over to McGregor Grant to present the financials. And to finish off, I’ll cover the outlook for the balance of the financial year before commencing the Q&A session.
Now turning to Slide 5, we will touch on the key highlights for Q2. We have made a lot of progress as a business to capture the value of SOZO and the new SOZO Pro in 3 large and growing market segments: breast cancer-related lymphedema; heart health; and wellness and weight management. While the rest of world sales were positive. And while U.S. BCRL sales for the quarter were disappointing, we remain very positive about the growth potential due to strong clinical demand, a strong sales team led by Scott Long, a growing emphasis on cancer survivorship and reimbursement now well in place. There are over 700 opportunities in our pipeline that we are focused on converting as well as growing with the extensive conference attendance and direct sales activities underway.
In terms of the financials, McGregor will go through the metrics in
Read the full article here